From Arrowhead Pharmaceuticals PASADENA, Calif.–(BUSINESS WIRE)–Jul. 17, 2023– Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it has filed an application for clearance to initiate a Phase 1/2 clinical trial… Read More »
Arrowhead files for regulatory clearance to start a Phase 1/2 study in FSHD
True Cost of FSHD survey
Preliminary findings from our survey to understand the economic impact of FSHD by June Kinoshita, FSHD Society As a growing number of drugs enter clinical trials for FSHD, a question… Read More »
Walkers and Wheelchairs 101
Not every person with FSHD will need a mobility device, but many will at some point. The many designs and brands on the market can be daunting.
Passion and hope at the IRC
The immeasurable value of face to face meetings by Raj Badiani, FSHD UK I was given the opportunity to attend the FSHD Society’s International Research Congress (IRC) in Milan this… Read More »
Advocacy and industry partners launch new global coalition to speed delivery of new therapies for FSHD
Project Mercury unites patients, industry, research and clinical communities in groundbreaking initiative from Fulcrum Therapeutics Today on World FSHD Day, the FSHD Society and Fulcrum Therapeutics announce the launch of… Read More »